Cardiol Therapeutics Inc. (TSE:CRDL) has released an update.
Cardiol Therapeutics Inc., a biotechnology company, has released its condensed interim consolidated financial statements for the first quarter of 2024, showing a decrease in total assets from CAD 36.7 million to CAD 31.1 million, and an increased net loss of CAD 9.1 million compared to CAD 7.1 million the previous year. The company’s cash and cash equivalents also saw a significant drop from CAD 34.9 million to CAD 28.6 million, indicating a challenging quarter for Cardiol.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
